Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06628453 · ClinicalTrials.gov registry record · NA
CGM for Management of Type 2 Diabetes in Pregnancy
A NA study of Pregnancy and Type 2 Diabetes Mellitus (T2DM), sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 564
- Enrollment target
- 7
- Study locations
NCT06628453 is a NA study of Pregnancy and Type 2 Diabetes Mellitus (T2DM) that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 564 participants, below the 870-participant average among 191 other Pregnancy trials with a reported enrollment target (35% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT06628453, a NA study of Pregnancy and Type 2 Diabetes Mellitus (T2DM), is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 564 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are: 1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose? 2. Does continuous glucose monitoring improve maternal diabetes control and other maternal outcomes compared to self-monitoring of blood glucose? 3. What other factors increase the risk of maternal and infant complications? Participants will: 1. Use continuous glucose monitoring or self-monitoring of blood glucose to monitor blood sugar control from enrollment until delivery 2. Have blood drawn at enrollment, 24 weeks, 34 weeks and delivery to measure hemoglobin A1c levels and store blood for future analysis 3. Complete surveys about social support, environmental stressors, diabetes distress and glucose monitoring satisfaction at research visits 4. Have umbilical cord blood collected at delivery for analysis
Conditions Studied
Interventions
- DEVICE CGM
Study Locations (7)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California at San Diego - San Diego
North Carolina
- University of North Carolina - Chapel Hill - Chapel Hill
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
South Carolina
- Prisma Health Greenville Memorial Hospital - Greenville
Texas
- University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2025-04-08 |
| Est. Completion | 2029-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06628453
The ClinicalTrials.gov registry entry for NCT06628453 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 564 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 870-participant average among 191 other Pregnancy trials with a reported enrollment target (35% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which CGM is the first listed.
NCT06628453 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Alabama, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06628453 about?
NCT06628453 is a clinical study titled "CGM for Management of Type 2 Diabetes in Pregnancy". The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2...
What is the current status of trial NCT06628453?
This trial is currently recruiting. It is a NA study. The enrollment target is 564 participants. The study started on 2025-04-08. Estimated completion is 2029-07.
What conditions does trial NCT06628453 study?
This clinical trial studies the following conditions: Pregnancy, Type 2 Diabetes Mellitus (T2DM).
What interventions are being tested in trial NCT06628453?
The interventions under investigation include: CGM (DEVICE).
Who is sponsoring clinical trial NCT06628453?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06628453 being conducted?
This trial has 7 study locations across Alabama, California, North Carolina, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Cocooned Moms Study
RECRUITING · NA
-
Feasibility of an ADAPTive Intervention to Improve Food Security and Maternal-Child Health
RECRUITING · NA
-
Enhancing Care & Outcomes for Patients During the First Postpartum Year
RECRUITING · NA
-
Mitigating Response to Stressors in Pregnant Women
RECRUITING · NA
-
Technology-Enhanced Therapy vs. Medication Monitoring for Buprenorphine Retention in Pregnant Persons
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.